Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 282

1.

Sub-2 Å Ewald curvature corrected structure of an AAV2 capsid variant.

Tan YZ, Aiyer S, Mietzsch M, Hull JA, McKenna R, Grieger J, Samulski RJ, Baker TS, Agbandje-McKenna M, Lyumkis D.

Nat Commun. 2018 Sep 7;9(1):3628. doi: 10.1038/s41467-018-06076-6.

2.

An Observational Study from Long-Term AAV Re-administration in Two Hemophilia Dogs.

Sun J, Shao W, Chen X, Merricks EP, Wimsey L, Abajas YL, Niemeyer GP, Lothrop CD, Monahan PE, Samulski RJ, Nichols TC, Li C.

Mol Ther Methods Clin Dev. 2018 Aug 4;10:257-267. doi: 10.1016/j.omtm.2018.07.011. eCollection 2018 Sep 21.

3.

Cryoprecipitate augments the global transduction of the adeno-associated virus serotype 9 after a systemic administration.

Chai Z, Zhang X, Rigsbee KM, Wang M, Samulski RJ, Li C.

J Control Release. 2018 Sep 28;286:415-424. doi: 10.1016/j.jconrel.2018.08.018. Epub 2018 Aug 11.

PMID:
30107215
4.

Nab Escaping AAV Mutants Isolated from Mouse Muscles.

Chai Z, Samulski RJ, Li C.

Bio Protoc. 2018 May 5;8(9). pii: e2841. doi: 10.21769/BioProtoc.2841.

5.

Double-stranded RNA innate immune response activation from long-term adeno-associated virus vector transduction.

Shao W, Earley LF, Chai Z, Chen X, Sun J, He T, Deng M, Hirsch ML, Ting J, Samulski RJ, Li C.

JCI Insight. 2018 Jun 21;3(12). pii: 120474. doi: 10.1172/jci.insight.120474. [Epub ahead of print]

6.

Impact of neutralizing antibodies against AAV is a key consideration in gene transfer to nonhuman primates.

Xiao W, Gao G, Ling C, Herzog RW, Xiao X, Samulski RJ.

Nat Med. 2018 Jun;24(6):699. doi: 10.1038/s41591-018-0062-2. No abstract available.

PMID:
29867233
7.

Blood-brain barrier shuttle peptides enhance AAV transduction in the brain after systemic administration.

Zhang X, He T, Chai Z, Samulski RJ, Li C.

Biomaterials. 2018 Sep;176:71-83. doi: 10.1016/j.biomaterials.2018.05.041. Epub 2018 May 26.

PMID:
29860139
8.

Efficient Capsid Antigen Presentation From Adeno-Associated Virus Empty Virions In Vivo.

Pei X, Earley LF, He Y, Chen X, Hall NE, Samulski RJ, Li C.

Front Immunol. 2018 Apr 19;9:844. doi: 10.3389/fimmu.2018.00844. eCollection 2018.

9.

AAV6 K531 serves a dual function in selective receptor and antibody ADK6 recognition.

Bennett AD, Wong K, Lewis J, Tseng YS, Smith JK, Chipman P, McKenna R, Samulski RJ, Kleinschmidt J, Agbandje-McKenna M.

Virology. 2018 May;518:369-376. doi: 10.1016/j.virol.2018.03.007. Epub 2018 Mar 30.

PMID:
29604478
10.

AAV8 virions hijack serum proteins to increase hepatocyte binding for transduction enhancement.

Pei X, He T, Hall NE, Gerber D, Samulski RJ, Li C.

Virology. 2018 May;518:95-102. doi: 10.1016/j.virol.2018.02.007. Epub 2018 Feb 16.

PMID:
29455066
11.

Inhibition of antigen presentation during AAV gene therapy using virus peptides.

Shao W, Chen X, Samulski RJ, Hirsch ML, Li C.

Hum Mol Genet. 2018 Feb 15;27(4):601-613. doi: 10.1093/hmg/ddx427.

PMID:
29272432
12.

Protein Phosphatase Inhibitor-1 Gene Therapy in a Swine Model of Nonischemic Heart Failure.

Watanabe S, Ishikawa K, Fish K, Oh JG, Motloch LJ, Kohlbrenner E, Lee P, Xie C, Lee A, Liang L, Kho C, Leonardson L, McIntyre M, Wilson S, Samulski RJ, Kranias EG, Weber T, Akar FG, Hajjar RJ.

J Am Coll Cardiol. 2017 Oct 3;70(14):1744-1756. doi: 10.1016/j.jacc.2017.08.013.

PMID:
28958332
13.

Application of polyploid adeno-associated virus vectors for transduction enhancement and neutralizing antibody evasion.

Chai Z, Sun J, Rigsbee KM, Wang M, Samulski RJ, Li C.

J Control Release. 2017 Sep 28;262:348-356. doi: 10.1016/j.jconrel.2017.08.005. Epub 2017 Aug 5.

PMID:
28789965
14.

AAV Gene Therapy for Alcoholism: Inhibition of Mitochondrial Aldehyde Dehydrogenase Enzyme Expression in Hepatoma Cells.

Sanchez AC, Li C, Andrews B, Asenjo JA, Samulski RJ.

Hum Gene Ther. 2017 Sep;28(9):717-725. doi: 10.1089/hum.2017.043. Epub 2017 Jun 2.

15.
16.

AAV-Nrf2 Promotes Protection and Recovery in Animal Models of Oxidative Stress.

Liang KJ, Woodard KT, Weaver MA, Gaylor JP, Weiss ER, Samulski RJ.

Mol Ther. 2017 Mar 1;25(3):765-779. doi: 10.1016/j.ymthe.2016.12.016.

17.

Systemic and Persistent Muscle Gene Expression in Rhesus Monkeys with a Liver De-Targeted Adeno-Associated Virus Vector.

Tarantal AF, Lee CCI, Martinez ML, Asokan A, Samulski RJ.

Hum Gene Ther. 2017 May;28(5):385-391. doi: 10.1089/hum.2016.130. Epub 2017 Jan 25.

18.

β-cell-specific IL-35 therapy suppresses ongoing autoimmune diabetes in NOD mice.

Manzoor F, Johnson MC, Li C, Samulski RJ, Wang B, Tisch R.

Eur J Immunol. 2017 Jan;47(1):144-154. doi: 10.1002/eji.201646493. Epub 2016 Nov 25.

19.

Direct interaction of human serum proteins with AAV virions to enhance AAV transduction: immediate impact on clinical applications.

Wang M, Sun J, Crosby A, Woodard K, Hirsch ML, Samulski RJ, Li C.

Gene Ther. 2017 Jan;24(1):49-59. doi: 10.1038/gt.2016.75. Epub 2016 Nov 11.

20.

Characterization of a novel adeno-associated viral vector with preferential oligodendrocyte tropism.

Powell SK, Khan N, Parker CL, Samulski RJ, Matsushima G, Gray SJ, McCown TJ.

Gene Ther. 2016 Nov;23(11):807-814. doi: 10.1038/gt.2016.62. Epub 2016 Sep 15.

Supplemental Content

Loading ...
Support Center